SARS-CoV-2 infection in patients with multiple myeloma: survey in 23 centers across Europe and USA

Dytfeld, D.; Radocha, J.; Hajek, R.; Cengiz-Seval, G.; Berkac, M.; Coriu, D.; Derman, B.; Jakubowiak, A.; Peceliunas, V.; Mikala, G.; Bolkun, L.; Hawrylecka, D.; Grosicki, S.; Tyczynska, A.; Zaucha, J. M.; Knopinska, W.; Semenczuk, G.; Morawska, M.; Giannopoulos, K.; Pula, A.; Rymko, M.; Charlinski, G.; Szeremet, A.; Kalicinska, E.; Usnarska, L.; Wrobel, T.; Jamroziak, K.; Druzd-Sitek, A.; Romejko-Jarosinska, J.; Sawicki, W.; Waszczuk-Gajda, A.; Juda, A.; Hus, M.; Gil, L.

Dytfeld, D.; Radocha, J.; Hajek, R.; Cengiz-Seval, G.; Berkac, M.; Coriu, D.; Derman, B.; Jakubowiak, A.; Peceliunas, V.; Mikala, G.; Bolkun, L.; Hawrylecka, D.; Grosicki, S.; Tyczynska, A.; Zaucha, J. M.; Knopinska, W.; Semenczuk, G.; Morawska, M.; Giannopoulos, K.; Pula, A.; Rymko, M.; Charlinski, G.; Szeremet, A.; Kalicinska, E.; Usnarska, L.; Wrobel, T.; Jamroziak, K.; Druzd-Sitek, A.; Romejko-Jarosinska, J.; Sawicki, W.; Waszczuk-Gajda, A.; Juda, A.; Hus, M.; Gil, L..

Acta Haematologica Polonica ; 54(2):82-85, 2023.

Article Dans Anglais | EMBASE | ID: covidwho-20235121

ABSTRACT

ABSTRACT

Introduction:

Despite several studies, the impact of coronavirus disease 2019 on patients with multiple myeloma remains uncertain. Material(s) and Method(s) We performed a survey that covered the period of the first and second waves of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic in 23 centers inseven countries. Out of 352 patients with myeloma and SARS-CoV-2, 23% died. Results/

Conclusions:

Logistic regression showed a lower risk of death among patients treated with proteasome inhibitor and a higher risk of death for those who had a severe or a very severe course of disease.Copyright © 2023 Sciendo. All rights reserved.

Mots clés

covid-19; myeloma; adult; aged; antiviral therapy; article; cancer chemotherapy; cancer patient; combination drug therapy; controlled study; coronavirus disease 2019/dt [Drug Therapy]; coronavirus disease 2019/pc [Prevention]; COVID-19 convalescent plasma treatment; Czech Republic; disease severity; female; health survey; human; Hungary; infection risk; Lithuania; major clinical study; male; mortality; multiple myeloma/dt [Drug Therapy]; multiple myeloma/th [Therapy]; nonhuman; pandemic; Poland; retrospective study; Romania; Severe acute respiratory syndrome coronavirus 2; stem cell transplantation; treatment response; Turkey (republic); United States; antineoplastic agent/dt [Drug Therapy]; antineoplastic agent/tm [Unexpected Outcome of Drug Treatment]; antineoplastic monoclonal antibody/dt [Drug Therapy]; dexamethasone/dt [Drug Therapy]; immunomodulating agent/cb [Drug Combination]; immunomodulating agent/dt [Drug Therapy]; melphalan/dt [Drug Therapy]; melphalan flufenamide/dt [Drug Therapy]; proteasome inhibitor/cb [Drug Combination]; proteasome inhibitor/dt [Drug Therapy]; remdesivir/dt [Drug Therapy]; SARS-CoV-2 convalescent plasma/dt [Drug Therapy]; SARS-CoV-2 vaccine/dt [Drug Therapy]; selinexor/dt [Drug Therapy]; tocilizumab/dt [Drug Therapy]; ventilator

Texte intégral

Imprimer

XML

Texte intégral: Disponible Collection: Bases de données des oragnisations internationales Base de données: EMBASE Type d'étude: Étude observationnelle / Étude pronostique langue: Anglais Revue: Acta Haematologica Polonica Année: 2023 Type de document: Article

Documents relatifs à ce sujet

MEDLINE

LILACS

LIS

Texte intégral

Imprimer

XML